💹 NASDAQ: BNOX - The Talk of Wall Street Right Now!

Just look at this chart! This company has been on some CRAZY SWINGS! -*ADVERTORIAL*- With biotech bulls expecting a turnaround, small-cap NASDAQ company Bionomics Ltd. should be high on your radar! Greetings Investors, 2023 could be the year that the biotech arena sees a major bounce. Easing interest rates and cooling inflation means that biotech companies could be primed for a bounce-back this year said [The Wall Street Journal]( in January. It’s no secret that the rising interest rate environment took a toll on the biotech industry in 2022. As inflation begins to decline all over the world, analysts are hopeful that this year will be a strong year for the biotech space. Especially small-cap biotech companies that may be very undervalued right now as they work on promising treatments. Merck CEO Robert Davis used the word "confident" more than 20 times in his presentation at the JPMorgan healthcare conference, setting the tone for how the biotech industry feels in 2023. This puts the spotlight on Bionomics Ltd. The company trades under the ticker symbol BNOX and is currently trading at around $4 a share. BNOX carries a high price target of $10 seen [HERE](. This estimate represents a 150%+ increase from the last price of $4! Even more impressively, 3 brokerages have also issued [1-year price targets]( for Bionomics' shares with forecasts ranging from $6.00 to $23.00. On average, they predict the company's share price to reach $14.50 in the next twelve months. This suggests a possible upside of 370% from the stock's current price! Two common conditions in mental health are social anxiety disorder (SAD) and post-traumatic stress disorder (PTSD). BNOX is addressing both! This clinical-stage biopharmaceutical company is developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical needs. BNOX has been bearish lately with a loss of 20% in the past couple of weeks but may have bottomed out. The exhaustion of selling pressure coupled with analysts forecasting hefty price targets on the stock could serve as catalysts for a major trend reversal soon! Biotech small-cap BNOX may be setting up for a significant bounce as analysts highly anticipate results from the company’s ATTUNE study! [pastedGraphic.png] Developing treatments for patients with underserved CNS disorders! []( NASDAQ: BNOX ABOUT THE COMPANY: Bionomics is a global, clinical-stage biopharmaceutical company developing a pipeline of novel, ion channel targeting drug candidates designed to transform the lives of patients suffering from serious Central Nervous System (“CNS”) disorders. [pastedGraphic_1.png] Targeting Distinct CNS Conditions with Neurotransmitter Imbalance Bionomics has a pipeline of novel therapeutic candidates targeting the treatment of serious central nervous system disorders for which there is a large unmet medical need. Development of our pipeline is accelerated through our partnering strategy, which allows multiple and diverse programs to be optimally developed. RECENT NEWS: BNOX’s dissent in recent weeks is attributed to the company announcing results from its Phase PREVAIL study of BNC210 for the acute treatment of Social Anxiety Disorder (SAD), which showed a [miss on the primary endpoint](. Despite [HC Wainwright]( downgrading the stock to “neutral,” the analyst pointed out that the formulation works, and encouraging data might help de-risk the ATTUNE study. Topline data from BNOX’s Phase 2b ATTUNE study is expected in mid-2023. And it’s important to note that the indication has also received Fast Track designation for PTSD! The analyst sees the possibility of a Breakthrough Therapy designation as no new therapy has been approved in about 20 years for PTSD! [pastedGraphic_2.png] This is a major reason to have your eyes glued to BNOX and the company’s developments. [pastedGraphic_3.png] The trial enrolled 151 adult patients with diagnosed SAD and who rated ≥ 70 on the Liebowitz Social Anxiety Scale at 15 sites in the U.S. Study participants were randomised 1:1:1 to receive a single oral dose of either a placebo or 225 mg BNC210 or 675 mg BNC210. After dosing, there was a 55-minute rest period followed by an introduction to the Public Speaking Challenge, a 2-minute anticipation-preparation period, and a 5-minute speech. The primary outcome measure was a self-assessment during the speaking challenge using the Subjective Units of Distress Scale (SUDS), a tool for quantifying the intensity of anxiety, fear, or distress on a scale from 0 to 100, with 0 indicating no distress and 100 representing the highest level. Secondary outcome measures included self-assessment with the State-Trait Anxiety Inventory (STAI), a commonly used measure of trait and state anxiety, and an assessment with the Negative Self-Statements During Public Speaking subscale (SSPS-N). About BNC210: BNC210 is BNOX’s proprietary molecule in development for the treatment of Social Anxiety Disorder (SAD), Post-Traumatic Stress Disorder (PTSD) and other anxiety disorders. As a negative allosteric modulator of the alpha 7 nicotinic acetylcholine receptor (α7 nAChR), BNC210 has a novel mechanism of action and extensive nonclinical and clinical studies have shown it has several properties which may be useful to treat PTSD, SAD and other anxiety disorders. BNC210 Holds the Potential to Addresses the Shortcomings of Existing Therapies! There is a significant need for improved therapeutics for SAD and PTSD with improved efficacy and response rates, fewer side effects and a faster onset of action, which we believe may be achieved by targeting a different mechanism of action. [pastedGraphic_4.png] A Phase 2b clinical trial, referred as ATTUNE study, is underway, evaluating BNC210 monotherapy treatment in approximately 200 PTSD patients and results are expected in the first half of 2023. The ongoing trial is a one-to-one randomized, double-blind, placebo-controlled, parallel two-arm (placebo or BNC210 900 mg twice daily) 12-week treatment study that will assess the efficacy and safety of our newly developed tablet formulation of BNC210. The primary efficacy endpoint of this trial is the effect of BNC210 compared to placebo on baseline to endpoint change in CAPS-5 total symptom severity scores after 12 weeks of treatment. In addition, several investigator and self-reported secondary efficacy endpoints related to CAPS-5 symptom cluster severity scores and anxiety and depression measures along with safety and tolerability endpoints will be reported. Past Clinical Trial Information: In clinical studies, BNC210 has exhibited anti-panic properties by reducing the number and intensity of panic symptoms in a human model of Panic Disorder. In patients with Generalized Anxiety Disorder (GAD), BNC210 has demonstrated anti-anxiety activity in a [behavioural model of threat avoidance]( and on anxiety scale scores (STAI). Using functional magnetic resonance imaging (fMRI), BNC210 was shown to [reduce hyperactivity in the amygdala of the brain]( a region where increased activity is associated with anxiety. About Social Anxiety Disorder: SAD is a significant and persistent fear of social and performance-related situations. One of the most common mental disorders in the United States, an estimated 31 million Americans will suffer from SAD at some point in their lives. SAD can interfere with a person’s ability to work, make it difficult to maintain friendships, family relationships, and romantic partnerships, cause a person to avoid lifestyle activities like dining out and traveling, and make normal parts of everyday life such as grocery shopping, calling a handyman, or picking up coffee challenging. Fifteen million, or seven percent, of American adults have Social Anxiety Disorder. More than 75% of people experience their first symptoms during their childhood or early teenage years. People with social anxiety disorder are also at an increased risk for substance use disorder and major depressive disorder. ([SOURCE]( About PTSD: Post-traumatic stress disorder (PTSD) is a disorder that develops in some people who have experienced a shocking, scary, or dangerous event. It is natural to feel afraid during and after a traumatic situation. Fear triggers many split-second changes in the body to help defend against danger or to avoid it. About 5 out of every 100 adults (or 5%) in the U.S. has PTSD in any given year. In 2020, about 13 million Americans had PTSD. Women are more likely to develop PTSD than men. About 8 of every 100 women (or 8%) and 4 of every 100 men (or 4%) will have PTSD at some point in their life. ([SOURCE]( THE BOTTOM LINE: [William Blair]( writes that the investors' focus will shift to the Phase IIb ATTUNE study of BNC210 in post-traumatic stress disorder (PTSD). The analyst has even reiterated an Outperform rating on BNOX. “Although the PREVAIL study did not statistically meet its primary endpoint, we have noted the consistent trends in improvement of endpoints in the BNC210-treated patients and continued strong safety and tolerability profile of BNC210 across the 13 clinical trials conducted to date,” commented Errol De Souza, Executive Chairman of Bionomics. “The findings indicate that BNC210’s novel mechanism of action through allosteric modulation of the α7 nicotinic acetylcholine receptor is promising and we remain committed to the ongoing Phase 2b ATTUNE Study in PTSD with topline data expected mid-2023.” BNOX recently appointed [Spyridon “Spyros” Papapetropoulos]( as President and Chief Executive Officer who has extensive experience in CNS clinical development to work with the Bionomics team to conduct further analysis on the PREVAIL Study data and consult with key opinion leaders and regulators in order to define next steps for the program. Dr. Papapetropoulos remarked, “The psychiatric and neurological disorders which Bionomics is targeting represent large, unsolved medical challenges for which patients need new options. I look forward to working with the Board, the management team and Bionomics employees in leading the Company as we prepare for its next stage of growth.” Another bright spot is that the company has a strong cash position that helps them continue operations to at least mid-2024. AND…. BNOX has a strategic partnership with Merck & Co., Inc with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions. Last year was a period of transition for biotech firms and there was a major stall. It is expected that small private biotech firms will make a comeback in the initial public offering market in the later part of 2023 as the rate of interest rate hikes slows down. BNOX could be gearing up for a major bounce and has stellar upside potential in the triple digits going by the price targets forecast on it! Start your research right away! Copyright 2022 © PTE.la is owned by IA Media LLC and operated by the owner of CareBear Marketing Group LLC and IR Agency LLC. [Disclaimer and Privacy]( more Information please contact Support@pte.la IA Media LLC, CareBear Marketing Group LLC and IR Agency LLC and their affiliates and control persons (the “Publisher”) are in the business of publishing favorable information and/or advertisements (the “Information”) about the securities of publicly traded companies (each an “Issuer” or collectively the “Issuers”) in exchange for compensation (the “Campaigns”). Persons receiving the Information are referred to as the “Recipients.” The person or entity paying the Publisher for the Campaign is referred to herein as the “Paying Party”. The Paying Party may be an Issuer, an affiliated or non-affiliate shareholder of an Issuer or another person hired by the Issuer or an affiliate or non-affiliate shareholder of the Issuer. The nature and amount of compensation paid to the Publisher for the Campaign and creating and/or publishing the Information about each Issuer is set forth below under the heading captioned, “Compensation”. This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security. IA Media LLC, CareBear Marketing Group LLC and/or IR Agency LLC, its managers, its employees, affiliates, and assigns (collectively the "Publisher") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above. To the maximum extent permitted by law, the Company disclaims all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete, or unreliable, or result in any investment or other losses. You received this message as part of your subscription to TST. TST is a free financial news and information website. We do not directly sell any products or offer any personal financial advice, nor do we advocate the purchase or sale of any security or investment for any specific individual. We also do not make any guarantee or warranty about what is advertised above. If you have questions or concerns about a product you’ve seen in one of our emails, we encourage you to reach out to that company directly. Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned by IA Media LLC, operated, and edited by the owner of CareBear Marketing Group LLC and IR Agency LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “TST” refers to IA Media LLC CareBear Marketing Group LLC and/or IR Agency LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares, we will list the information relevant to the stock and the number of shares here. We do not own any shares in BNOX. We have been compensated up to Two-Hundred and Fifty Thousand Dollars Cash ($250,000) via bank wire transfer from a third-party Open Market Media Group for a 3 Day Marketing Program regarding BNOX with a start date of 3/06/2023 to 3/08/2023.TST’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding our alerts. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, TST often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. If you clicked on a link to this page, then this Disclaimer is applicable to the Information you received or will receive about the Issuers mentioned under the heading “COMPENSATION” at the bottom of this Disclaimer. METHODS OF DISSEMINATION The Publisher may use various types of media (the “Media”) to disseminate the Information, at its discretion without notice to Recipients. The Information may be published on and/or through any or all the non-exclusive methods below: Ticker Tags (as defined under heading “DISCLAIMERS AND RISKS” websites owned, controlled and/or operated by the Publisher including but not limited to; TopStockTips.com, PTE.la, MomentumStocks.io, BullishCharts.com; websites owned and/or operated by the Publisher’s affiliates and non-affiliates, online communities, financial forums, trader and investor chat rooms, social media platforms and/or newsletters using online identities some or all of which may or may not be anonymous, text message alerts, audio services, online live interviews, news outlets located, coordinated or paid by the Publisher, email communications, and other communications sent to the Recipients from time to time. push notifications influencers podcasts online interviews audio ads banner ads native ads responsive ads DISCLAIMERS AND RISKS An investment in the Issuers is subject to numerous risks including but not limited to those set forth in this Disclaimer. Some but not all of these risks include: Ticker Tagging attaches an Issuer’s name and symbol to that of a larger more successful company to create interest. Ticker Tags are click bait to get a reader’s attention so that they click on a link. Information contained in Ticker Tags is not true or complete and its sole purpose is to cause a Recipient to click a link to a webpage so that the Recipient is provided with the Information. The Campaigns vary between Issuers. Campaigns may consist of dissemination though one or more types of Media while other Campaigns may use one or more different types of Media. Different types of Media may be disseminated at different times to different Recipients. Some types of the Media may be disseminated for longer periods of time than other types of Media. The Media may be coordinated in a manner designed to create an increase in the volume and trading price of an Issuer’s securities for a temporary period of time. You should not consider increases in volume and price of an Issuer’s securities during a Campaign as an indication or measure of value or price. The Publisher may disseminate the Information multiple times and at different times that are minutes, hours, days, weeks or even months apart. As such, the Information may be viewed by Recipients at different times that are minutes, hours, days or even weeks apart. Typically, the earlier the Recipient receives the Information, the lower the price at which he or she can purchase an Issuer’s securities. As a result, the later a Recipient receives the Information, the more likely it is that the Recipient will suffer increased trading losses if he purchases the securities of an Issuer. Recipients who receive the Information at later times will likely pay prices which are higher than the prices paid by Recipients who receive the information earlier in the Campaign. Temporary volume and price increases will likely result from Recipients buying an Issuer’s securities during the Campaign. If you invest in an Issuer’s securities based upon these temporary volume and price increases, you will likely lose your investment. The Publisher does not publish negative information because it is compensated to publish only favorable information. The Information is a one-sided incomplete favorable snapshot and as such, the Information is not balanced, complete, accurate, truthful or reliable. If you rely on the Information in making an investment decision, you will likely lose your investment. The Information does not include the information necessary to make an informed investment decision. If you rely on the Information in making an investment decision, you will likely lose your investment. If you invest in the Issuers, you should be prepared to lose your entire investment without a change to your standard of living. The Publisher receives the Information from the Issuer, Paying Party or other sources such as press releases, stock message boards or websites, the OTC Markets, Google, NASDAQ, NYSE, Yahoo, Bing, the Securities and Exchange Commission’s (“SEC”) Edgar database or other available sources. Information derived from these sources should not be deemed to be reliable, true or complete. The Publisher does not verify or assert the truthfulness, completeness, accuracy or reliability of the Information. The Publisher conducts no due diligence or investigation of the Issuers or their securities and it does not receive any verification from the Issuers concerning the truthfulness or completeness of the Information. The Publisher does not review, nor does it have the sophistication or resources necessary to analyze the financial condition, operations, business, management, risks or prospects involved in an investment in the securities of any of the Issuers. If you rely on the Information in making an investment decision, you will likely lose your investment. Past results of an Issuer do not guarantee future performance. The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of an Issuer’s future stock price or future financial performance. If you rely on the Information in making an investment decision, you will likely lose your investment. If the Information states that an Issuer’s securities are consistent with a future economic trend, then it should not be relied upon and should be considered as satire or an error. Even if a Recipient’s own independent research indicates that an Issuer’s securities are consistent with future economic trends, each Recipient should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and government may react in unforeseen ways and be affected by behavioral biases that The Publisher is unable to predict; (c) human and social factors may outweigh future economic trends that the Publisher state may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of new circumstances and situations in which uncertainty becomes reality rather than predicted economic outcome; or (f) if the trend predicted involves a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies. If you rely on the Information in making an investment decision, you will likely lose your investment. The Publisher is not nor is it qualified to act as: (i) an investment adviser or an entity engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal or state level, (ii) a broker-dealer or an individual acting in the capacity of a registered representative or broker-dealer, (iii) a stock picker, (iv) a securities trading or investment expert, (v) a securities researcher or analyst, (vi) a financial planner or one who engages in financial planning, (vii) a party who provides advice about buy, sell or hold recommendations as to specific securities; (viii) a clairvoyant, physic or fortune teller, or (ix) a party or an agent offering securities for sale or soliciting their purchase. References in the Information that refer to a security as a “stock pick” means it is a stock advertised by the Publisher and is not an indication the Issuer or its securities have been picked, chosen, selected, researched or recommended by the Publisher or that the Publisher is qualified to pick, chose, select, research or recommend investments or securities. If you rely on the Information in making an investment decision, you will likely lose your investment. The Information should only be used, at most, and if at all, as a starting point for a Recipient to conduct a thorough investigation of the Issuer and its securities. If a Recipient relies on the Information in making an investment decision, the Recipient will likely lose most, if not all, of his or her investment. Under no circumstances should Recipients rely on the Information to make an investment decision or for any other purpose. If you rely on the Information in making an investment decision, you will likely lose your investment. There is a high degree of risk in an investment in the securities of the Issuers. Recipients may encounter difficulties determining what, if any, portions of the Information are material or non-material, making it all the more imperative that each Recipient conducts its own independent investigation of the Issuer and its securities with the assistance of its legal, tax and financial advisors. Each Recipient is expressly advised to consult with its own financial, legal or other advisers prior to an investment in the securities of an Issuer. Recipients should review with these advisers, the filings and information that may be accessed at sec.gov or www.otcmarkets.com including: (i) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D), and (ii) reviewing Information and Disclosure Statements and financial reports filed with the OTCMarkets.com. Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or their securities could have negative legends and designations at otcmarkets.com. Additionally, Recipients and their advisors should obtain and review: (i) publicly available information contained in commonly known search engines such as google, and (ii) investment guides at www.sec.gov and www.finra.org. If an Issuer is an SEC reporting company, it could be delinquent (not current) in its periodic reporting obligations (i.e., in its quarterly and annual reports) with the SEC, or if it is an OTC Markets Pink Sheet quoted company, it may be delinquent in its Pink Sheet reporting obligations, which may result in OTC Markets posting a negative legend pertaining to the Issuer at www.otcmarkets.com, as follows: (i) “Limited Information” for companies with financial reporting problems, economic distress, or that are unwilling to file required reports with the Pink Sheets; (ii) “No Information,” which characterizes companies that are unable or unwilling to provide any disclosure to the public markets, to the SEC or the Pink Sheets; and (iii) “Caveat Emptor,” signifying buyers should be aware that there is a public interest concern associated with a company’s illegal spam campaign, questionable stock promotion, known investigation of a company’s fraudulent activity or its insiders, regulatory suspensions or disruptive corporate actions. Recipient’s use of the Information is at its own risk. The Information is provided “as is” with no warranties of any type, without limitation. The Publisher is not responsible or liable for any person’s use of the Information or any success or failure that is directly or indirectly related to such person’s use of the Information because the Publisher has specifically stated that the information is not reliable and should not be relied upon for any purpose including an investment. The Publisher is not responsible for omissions or errors in the Information and the Publisher is not responsible for actions taken by any person who relies upon the Information. The Publisher makes no warranty or representation about the Information, including its completeness, accuracy, truthfulness or reliability. The Publisher disclaims, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. The Publisher, the Paying Party or other service providers including stock promoters and advertisers (“Selling Parties”) could receive free-trading securities of an Issuer: (i) as compensation, (ii) in private or open market transactions at prices lower than the market price or price paid by Recipients, and/or (iii) in open market transactions before, during and after the Campaigns. Selling Parties may sell their securities of an Issuer at any time during the Campaigns, even while the Publisher publishes the Information instructing or encouraging Recipients to purchase securities of the Issuer. When Selling Parties sell their securities, the volume and trading price of the Issuer’s securities will likely decline. This will reduce the price at which Recipients can sell their securities and likely cause Recipients to suffer trading losses. Selling Parties may sell securities of the Issuers for less than the target prices set forth in the Information and Selling Parties may profit by selling its securities during the Campaigns while Recipients have a loss. When Selling Parties acquire, purchase or sell the securities of an Issuer, it could (i) cause significant volatility in the Issuer’s securities; (ii) if purchasing, cause temporary but unrealistic increases in volume and price of the Issuer’s securities; and (iii) if selling, cause the Issuer’s stock price and trading volume to decline dramatically resulting in Selling Parties making substantial profits while Recipients who purchase during the Campaign experience significant losses. The Campaigns are designed to increase the trading price of the Issuers’ securities by encouraging the Recipients of the Information to purchase an Issuer’s securities despite that the securities may not be a good investment, and the trading price of the Issuer’s securities will dramatically decline when the Campaign ends. If you rely on the Information in the Campaigns when making an investment decision, you will likely lose your investment. If the Issuer’s trading price increases during the Campaign, it is likely the result of buying activity caused by the Campaign and such increase does not reflect the Issuer’s prospects, financial condition or an increase in the value of the Issuer’s securities. If you rely on this buying activity when making an investment decision, you will likely lose your investment. If Selling Parties hold or are compensated in improperly free-trading securities of the Issuers, either directly or indirectly, the Selling Parties and the Issuer could be the subject to an SEC Enforcement action, including allegations of an illegal distribution in violation of Section 5(a) and 5(c) of the Securities Act which could cause you to lose your investment. The Publisher may hire service providers to disseminate the Information about the Issuers and the Publisher may not have control over such parties. The Publisher does do not verify the Information it receives from any party or information disseminated by other service providers. As such, you should not rely on the Information when making an investment decision. The Information may contain statements asserting that an Issuer’s stock price has increased over a certain period of time which may reflect an arbitrary period of time, and such statements are not predictive or of any analytical quality. As such, Recipients should not rely on the Information as an analysis of the present or future potential of an Issuer or its securities. If you rely on the Information, you will likely lose your investment. If any percentage gain of an Issuer’s securities from the previous day’s close is included in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to an investment in an Issuer. If you rely on the previous days close as an indication of performance, it could cause you to lose your investment. Past results of an Issuer do not guarantee future performance. The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of an Issuer’s future stock price or future financial performance. Recipients should consider the securities of the Issuers as high risk, unstable, unpredictable and illiquid which may make it difficult for Recipients to sell any securities of the Issuers that they purchase. During the Campaign the trading volume and price of the securities of each Issuer will likely increase significantly. When the Campaign ends, the volume and price of the Issuer will likely decrease dramatically. As a result, Recipients who purchase during the Campaign or as a result of the Campaign will probably lose most, if not all, of their investment. MM’s publication of the Information involves actual and material conflicts of interest including but not limited to the following: The Publisher receives monetary and/or securities compensation in exchange for disseminating the Information about the Issuers. The Publisher only publishes favorable information about the Issuers and does not publish any negative information about the Issuers. The Paying Parties likely hold securities of an Issuer which they acquired from the Issuer, affiliate or non-affiliate shareholders or from its own open market purchases before, during or after the Campaign. The Paying Parties may have acquired these securities for services or at prices lower than that paid by Recipients. The Paying Parties may sell these securities during the Campaign while the Publisher publishes the Information recommending that Recipients purchase. Selling by a Paying Party will likely cause Recipients who purchase securities of any of the Issuers to suffer losses. DISCLAIMER COMPENSATION We do not own any shares in BNOX. We have been compensated up to Two-Hundred and Fifty Thousand Dollars Cash ($250,000) via bank wire transfer from a third-party Open Market Media Group for a 3 Day Marketing Program regarding BNOX with a start date of 3/06/2023 to 3/08/2023. PTE Team 9 Downing street Newark NJ 07105 USA [Unsubscribe]( | [Change Subscriber Options](